Tag: CYTX

Blue Horseshoe Stocks: BIOC, Options Ideas & More


Biocept, Inc. BIOC
–
BIOC came off of yesterday morning’s extended watchlist making a big move to start the week. The stock traded up from a low of 1.71 and ran as high as 2.95, registering as an intraday increase of 72%  on heavy volume in the neighborhood of 17X the 30-day running average.

After pulling back slightly into the close at 2.20, BIOC is presently gapping up in the premarket this morning( High of 2.64), so we’re going to keep it on our watchlist for the time being.

The strong session came in conjunction with a positive PR which hit the wires yesterday:

SAN DIEGO, Feb 23, 2015 (GLOBE NEWSWIRE via COMTEX) — Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that its blood-based diagnostic, OncoCEE-BR(TM), was used to determine hormonal status of metastatic breast cancer patients in a prospective study performed at the Columbia University College of Physicians and Surgeons in New York City. Findings from the Columbia study were recently published in the peer-reviewed journal Clinical and Translational Oncology.>>> FULL PR

Direxion Daily Russia Bear 3X ETF (RUSS)

The idea we brought forth yesterday of monitoring RUSS, which trades inversely with the Russian economy, is probably going to be one that we follow for a longer period of time given the drawn out nature of the events currently playing out in the Ukraine, and how they’re affecting Russia.

That being said, we did see some immediate upward price action as RUSS ran into the close, recording a daily trading range from 12.58 – 13.74, a modest, yet solid 9% appreciation on the day.

Added Note:

We also want to make note of a proposed joint venture in the works between two companies whose stocks we’ve mentioned in the past: First Solar, Inc. FSLR and SunPower Corp. SPWR. Both stocks began to move on word of a possible IPO for a new vehicle to be comprised of existing assets from each party. We’re going to keep them on watch as we await further updates on the situation.

They’re both gapping up further this morning, so we’ll be on the lookout for potential dip-and-rip scenarios caused by profit-taking. In such an event, we’ll be fixating on In-the-money Weekly Calls for options daytrading possibilities.

TEMPE, Ariz. and SAN JOSE, Calif., Feb. 23, 2015 /PRNewswire/ — First Solar, Inc. (FSLR) and SunPower Corp. (SPWR) announced today that they are in advanced negotiations to form a joint YieldCo vehicle (the YieldCo) to which they each expect to contribute a portfolio of selected solar generation assets from their existing portfolio of assets. Upon the execution of a master formation agreement, the parties intend to file a registration statement with the Securities and Exchange Commission (the SEC) for an initial public offering of limited partner interests in the YieldCo (the IPO). >>> FULL PR

Extended Watchlist:
CAPN, EYES, CYTX, CHGG, AXN

Blue Horseshoe Stocks: ABIO Recap & More

ARCA BioPharma, Inc. ABIO

Our top performer from yesterday’s report was most assuredly ABIO. We tagged this play after noticing that it had announced being granted orphan drug status by the FDA for “rNAPc2” as a potential treatment of viral hemorrhagic fever post-exposure to the Ebola virus.

Fresh FDA-related plays can often provide a healthy move to take advantage of, and that’s just what we got from ABIO, The stock traded in a range from .82-1.03, an intraday increase of 25% on nearly ten times the 3-month average volume.

Our long-time readers might recall our coverage of this stock last year in December, which sort of got lost in the shuffle that was the hysteria created by the “Green Rush”. We tracked the stock from the low 1.40’s to over 2.20 over a period of a few weeks, so it will be interesting to see if history continues to repeat itself with ABIO, especially with the stock coming off of it 52-week low on Tuesday.

CYREN Ltd. CYRN

We also wanted to acknowledge the early morning move made by another of the stocks we mentioned in yesterday’s newsletter, CYRN. It bolted out of the gate, quickly running from 2.22 to 2.67, a 20% spike within the first 15 minutes of the session.

The stock got hammered into the close quite a bit, so we’ll be open to the possibility of seeing some bounce action, provided it can hold support at or above the 50DMA of 1.75.

Office Depot, Inc. ODP

ODP is in the midst of making a big move on the heels of large activist investor Starboard Value taking up a position which equates to 6% of ODP’s total shares. It also upped its stake in Staples to 10% fueling speculation that it could create pressure for the two office supply giants to merge. It will definitely be a story that we’ll be interested to follow moving forward.

Extended Watchlist:
GPT, RGDX, CYTX, DRD

Blue Horseshoe Stocks: LXRP News Update & FDA-Related Plays

Lexaria Corp. LXRP

Following our initial report on LXRP yesterday, the stock had a productive session as it traded in a range from .095 to a high of .108, an intraday gain of 14% on roughly 2.5X the monthly average volume. It closed at .102 holding more than half of the day’s gains, which is generally a good sign.

We promised to relay any further updates regarding the current status of LXRP, and sure enough the company published a fresh PR this morning containing another major development. It relates to the sale of Lexaria’s domestic oil assets, which we mentioned in yesterday’s report, becoming final with all funds received. It provides LXRP with a cash infusion of $1.4M which will facilitate a clearing of all debt currently on the books, as well as advance the company’s plans to release a CBD-infused tea (infusion method is patent pending) via a new online sales portal. With the rate at which LXRP has been executing its strategies, we expect to hear about the opening of that website any day now.

KELOWNA, BC / ACCESSWIRE / December 10, 2014 / Lexaria Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce the sale of all its Belmont Lake oil assets for $1.4 million in cash has closed and all money received. Lexaria congratulates the new owners for having purchased a fine asset. >> FULL PR

FDA-Related News

We caught a couple of FDA news plays on this morning’s scan that we’ll want to keep an eye on:

ARCA BioPharma, Inc. ABIO has reported that the FDA “has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure to Ebola virus.” >> VIEW PR

Cytori Therapeutics, Inc. CYTX announced that the FDA granted approval “for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.” >> VIEW PR

Extended Watchlist:
 CYRN, SYMX, SNSS